Lucid Diagnostics (LUCD) Equity Average (2021 - 2025)
Lucid Diagnostics (LUCD) has disclosed Equity Average for 5 consecutive years, with $16.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average rose 50.99% year-over-year to $16.8 million, compared with a TTM value of $16.8 million through Sep 2025, up 50.99%, and an annual FY2024 reading of $1.5 million, down 85.15% over the prior year.
- Equity Average was $16.8 million for Q3 2025 at Lucid Diagnostics, up from $1.2 million in the prior quarter.
- Across five years, Equity Average topped out at $50.6 million in Q1 2022 and bottomed at -$22.0 million in Q3 2021.
- Average Equity Average over 5 years is $12.8 million, with a median of $12.5 million recorded in 2024.
- The sharpest move saw Equity Average surged 4687.35% in 2024, then tumbled 99.85% in 2025.
- Year by year, Equity Average stood at $15.3 million in 2021, then skyrocketed by 65.27% to $25.3 million in 2022, then plummeted by 99.52% to $122500.0 in 2023, then soared by 4687.35% to $5.9 million in 2024, then surged by 187.3% to $16.8 million in 2025.
- Business Quant data shows Equity Average for LUCD at $16.8 million in Q3 2025, $1.2 million in Q2 2025, and $7000.0 in Q1 2025.